Moderna/NIH began Phase 1 vaccine trial

On March 16, 2020, the NIH announced the first participant in the Phase 1 study of Moderna’s mRNA-1273  vaccine candidate was dosed. A total of 63 days from sequence selection to first human dosing.

In August 2020, a petition was filed to halt the trials and insist that adverse reactions are tracked, and another in November for the efficacy end-points.  Also a FOIA submitted in May 2020 eventually allowed the Phase 1 data to be released to the public with redactions. [1, 2]

NIH, the very group developing and promoting vaccines, NIAID and it’s employees will personally earn millions from the Moderna vaccines due to their patent ownership.

Moderna’s COVID-19 vaccine timeline, their very first product.